SCHEMBL25306149

SCHEMBL25306149

Nc1nc2ccc(Oc3ccncc3)cc2s1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 6/20 0.75
NPC1 O15118 4/20 0.75
TP53 P04637 3/20 0.75
SMN1; SMN2 Q16637 3/20 0.75
MAPT P10636 2/20 0.75
HTT P42858 2/20 0.75
CYP3A4 P08684 5/20 0.62
CYP1A2 P05177 2/20 0.62
CYP2C19 P33261 1/20 0.62
PIK3CD O00329 5/20 0.60
PIK3CA P42336 4/20 0.60
PIK3CG P48736 4/20 0.60
PI4KA P42356 4/20 0.60
PI4KB Q9UBF8 4/20 0.60
PIK3CB P42338 3/20 0.60
PIP5K1C O60331 3/20 0.60
HSD17B10 Q99714 2/20 0.57
GAA P10253 2/20 0.57
SCN4A P35499 2/20 0.57
ALDH1A1 P00352 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31114514 1.00 RAB9A (0.75) RAB9ANPC1TP53SMN1; SMN2MAPT
SCHEMBL20568080 0.90 RAB9A (0.84) RAB9ANPC1TP53SMN1; SMN2MAPT
SCHEMBL14397078 0.87 RAB9A (0.58) RAB9ANPC1TP53SMN1; SMN2MAPT
SCHEMBL7285684 0.86 RAB9A (1.00) RAB9ANPC1TP53SMN1; SMN2MAPT
SCHEMBL7286497 0.84 CYP3A4 (0.82) RAB9ANPC1TP53SMN1; SMN2MAPT
SCHEMBL21186207 0.84 RAB9A (0.70) RAB9ANPC1TP53SMN1; SMN2MAPT
SCHEMBL9722831 0.84 RAB9A (0.75) RAB9ANPC1TP53SMN1; SMN2MAPT
SCHEMBL6067934 0.84 RAB9A (0.75) RAB9ANPC1TP53SMN1; SMN2MAPT
SCHEMBL31114771 0.84 RAB9A (0.75) RAB9ANPC1TP53SMN1; SMN2MAPT
SCHEMBL7285119 0.84 RAB9A (0.75) RAB9ANPC1TP53SMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250382273-A1 BENZOTHIAZOLE ANAOLOGUES AND USE THEREOF AS BOOSTERS OF ANTI TUBERCULOSIS DRUGS INST NAT SANTE RECH MED (FR) 2025-12-18 US disclosed
EP-4460500-A1 BENZOTHIAZOLE ANAOLOGUES AND USE THEREOF AS BOOSTERS OF ANTI TUBERCULOSIS DRUGS INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE - INSERM (FR) 2024-11-13 EP disclosed
WO-2023131649-A1 BENZOTHIAZOLE ANAOLOGUES AND USE THEREOF AS BOOSTERS OF ANTI TUBERCULOSIS DRUGS INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 2023-07-13 WO disclosed
WO-2023131649-A1 BENZOTHIAZOLE ANAOLOGUES AND USE THEREOF AS BOOSTERS OF ANTI TUBERCULOSIS DRUGS INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 2023-07-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250382273-A1 BENZOTHIAZOLE ANAOLOGUES AND USE THEREOF AS BOOSTERS OF ANTI TUBERCULOSIS DRUGS BBOX1, NDUFB6, NDUFB5 RAB9A 2727/4885NPC1 3115/4885TP53 1893/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.